Pirfenidone: Treatment for Idiopathic Pulmonary Fibrosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

Pirfenidone (Esbriet) is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Pirfenidone is an approved pharmacological agent for the treatment of idiopathic pulmonary fibrosis (IPF). In this video, shared by Demystifying Medicine, a youtube channel from McMaster University, learn more about how this drug can be used as a treatment for IPF, its effects and mechanism of action.

Learn more about pulmonary fibrosis: http://bit.ly/1VElTQA

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.